SG Americas Securities LLC Takes Position in Tempus AI, Inc. (NASDAQ:TEM)

SG Americas Securities LLC bought a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,032 shares of the company’s stock, valued at approximately $372,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Squarepoint Ops LLC bought a new stake in Tempus AI in the second quarter worth $633,000. Millennium Management LLC purchased a new stake in Tempus AI during the second quarter valued at $8,067,000. The Manufacturers Life Insurance Company purchased a new stake in Tempus AI during the second quarter valued at $946,000. Carnegie Investment Counsel purchased a new stake in Tempus AI in the third quarter worth about $7,936,000. Finally, Exchange Traded Concepts LLC purchased a new stake in Tempus AI in the third quarter worth about $3,458,000. 24.22% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and set a $56.00 target price on shares of Tempus AI in a research report on Tuesday, January 14th. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and raised their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Bank of America raised their price objective on Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Loop Capital decreased their price target on Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Finally, Wolfe Research started coverage on Tempus AI in a research note on Friday, December 13th. They set an “outperform” rating and a $60.00 price target for the company. Three analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.36.

Tempus AI Price Performance

Shares of NASDAQ:TEM opened at $61.54 on Tuesday. Tempus AI, Inc. has a 12-month low of $22.89 and a 12-month high of $79.49. The business’s fifty day simple moving average is $44.14 and its 200-day simple moving average is $48.44. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17.

Insider Activity

In other Tempus AI news, CAO Ryan M. Bartolucci sold 13,770 shares of Tempus AI stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $60.00, for a total transaction of $826,200.00. Following the completion of the sale, the chief accounting officer now owns 57,237 shares of the company’s stock, valued at approximately $3,434,220. The trade was a 19.39 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Andrew Polovin sold 51,504 shares of the business’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $42.39, for a total value of $2,183,254.56. Following the completion of the transaction, the executive vice president now directly owns 246,085 shares of the company’s stock, valued at approximately $10,431,543.15. This trade represents a 17.31 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 2,037,702 shares of company stock worth $89,449,651.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.